All In Biotech

NDA 206814 · Genus Lifesciences

Pokonza

Potassium Chloride · Oral

Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Dec 22, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9,299

2,122 Phase 3, 968 recruiting

FAERS reports

93,855

69,878 serious, 13,688 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 22, 2026.

POKONZA ® (Potassium Chloride Oral Solution, USP) is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient. POKONZA ® (Potassium Chloride Oral Solution, USP) is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient. ( 1 )

Mechanism: The potassium ion (K+) is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulses; the contraction of cardiac, skeletal, and smooth muscle; and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 mEq to 160 mEq per liter. The normal adult plasma concentration is 3.5 mEq to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane....

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • POKONZA · POTASSIUM CHLORIDE 10MEQ/15ML · SOLUTION, ORAL · Prescription
  • POTASSIUM CHLORIDE · POTASSIUM CHLORIDE 20MEQ/15ML · SOLUTION, ORAL · Prescription · TE AA
  • POTASSIUM CHLORIDE · POTASSIUM CHLORIDE 40MEQ/15ML · SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.

All 9,299 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea6,883
  • dyspnoea6,840
  • nausea6,627
  • fatigue6,413
  • death4,665
  • pneumonia4,544
  • headache4,281
  • vomiting4,216
  • asthenia4,206
  • off label use4,119
  • dizziness4,051
  • pain3,918

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004901
20051,824
20061,348
20071,683
20082,435
20092,665
20102,185
20112,587
20123,568
20132,074
20142,486
20153,933
20164,707
20174,800
20185,794
20195,661
20205,671
20216,017
20226,667
20236,693
20247,494
20257,576
20265,080

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Potassium Chloride (Potassium Chloride In Water)

2024 spending

$2K

Beneficiaries

48

103 claims

Per beneficiary

$52

$0.04 per unit

View as table
YearSpending
2020$5,527
2021$4,983
2022$2,192
2023$2,121
2024$2,484

Part D: Potassium Chloride* (Potassium Chloride)

2024 spending

$291M

Beneficiaries

3,573,756

14,480,710 claims

Per beneficiary

$81

$0.24 per unit

View as table
YearSpending
2020$481,853,924
2021$426,208,555
2022$413,879,866
2023$396,019,205
2024$290,918,304

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,091 on PubMed

Sponsor: Genus Lifesciences · Also marketed as Potassium Chloride

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.